The medical device firm reported adjusted earnings above analyst forecasts, driving a post-market stock increase.
Delcath Systems posted Q1 2026 adjusted earnings per share above consensus estimates, signaling stronger-than-expected operational performance. The company did not disclose the exact EPS figure but confirmed it exceeded market expectations.
Analysts had anticipated a narrower loss for the quarter, following a challenging prior period marked by supply chain disruptions. Revenue growth also accelerated compared to Q4 2025, though specific figures remain undisclosed.
Shares rose in extended trading, reflecting investor optimism over the earnings beat and improved financial outlook.